Sirtex Medical Limited
(ASX:SRX) has announced research groups in Paris and Singapore will combine results from their respective cancer drug trials to fast-track analysis.
Both studies are investigating the efficacy of SIR-spheres in treating inoperable primary liver cancer.
Sirtex Chief Medical Officer David Cade has indicated combining clinical data from both studies will allow investigators to draw more robust conclusions on the efficacy of the treatment.
Results of the meta-analysis are expected to be available during the 2017 calendar year.
Sirtex Medical Limited reported a net profit of $53.6 million at 30 June 2016.
